CD274 and non-small cell lung carcinoma: This phase 2/3 trial aims to compare the effectiveness of different treatments in patients with advanced non-squamous NSCLC who have experienced disease progression after prior anti-PD-L1 therapy and platinum doublet-based chemotherapy.